PI3K Delta Inhibitor in Relapsed / Refractory Autoimmune Hemolytic Anemia Patients After Receiving Two or More Lines of Therapy
Conditions:   Autoimmune Hemolytic Anemia;   Failure of Two Rounds of Treatment Intervention:   Drug: Linperlisib Sponsors:   Institute of Hematology & Blood Diseases Hospital;   YL-Pharma Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 9, 2023 Category: Research Source Type: clinical trials

British Axial Spondyloarthritis Inception Cohort
Condition:   Axial Spondyloarthritis Intervention:   Other: No intervenetion Sponsors:   The Leeds Teaching Hospitals NHS Trust;   Novartis;   Pfizer;   UCB Pharma Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 9, 2023 Category: Research Source Type: clinical trials

Efficacy and Safety of PI3K Inhibitors in Relapsed/Refractory Large Granular T Lymphocytic Leukemia
Condition:   Relapsed/Refractory Large Granular T Lymphocytic Leukemia Intervention:   Drug: Linperlisib Sponsors:   Institute of Hematology & Blood Diseases Hospital;   YL-Pharma Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 9, 2023 Category: Research Source Type: clinical trials

PI3K Delta Inhibitor in Relapsed / Refractory Autoimmune Hemolytic Anemia Patients After Receiving Two or More Lines of Therapy
Conditions:   Autoimmune Hemolytic Anemia;   Failure of Two Rounds of Treatment Intervention:   Drug: Linperlisib Sponsors:   Institute of Hematology & Blood Diseases Hospital;   YL-Pharma Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 9, 2023 Category: Research Source Type: clinical trials

British Axial Spondyloarthritis Inception Cohort
Condition:   Axial Spondyloarthritis Intervention:   Other: No intervenetion Sponsors:   The Leeds Teaching Hospitals NHS Trust;   Novartis;   Pfizer;   UCB Pharma Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 9, 2023 Category: Research Source Type: clinical trials

Efficacy and Safety of PI3K Inhibitors in Relapsed/Refractory Large Granular T Lymphocytic Leukemia
Condition:   Relapsed/Refractory Large Granular T Lymphocytic Leukemia Intervention:   Drug: Linperlisib Sponsors:   Institute of Hematology & Blood Diseases Hospital;   YL-Pharma Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 9, 2023 Category: Research Source Type: clinical trials

PI3K Delta Inhibitor in Relapsed / Refractory Autoimmune Hemolytic Anemia Patients After Receiving Two or More Lines of Therapy
Conditions:   Autoimmune Hemolytic Anemia;   Failure of Two Rounds of Treatment Intervention:   Drug: Linperlisib Sponsors:   Institute of Hematology & Blood Diseases Hospital;   YL-Pharma Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 9, 2023 Category: Research Source Type: clinical trials

British Axial Spondyloarthritis Inception Cohort
Condition:   Axial Spondyloarthritis Intervention:   Other: No intervenetion Sponsors:   The Leeds Teaching Hospitals NHS Trust;   Novartis;   Pfizer;   UCB Pharma Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 9, 2023 Category: Research Source Type: clinical trials

Efficacy and Safety of PI3K Inhibitors in Relapsed/Refractory Large Granular T Lymphocytic Leukemia
Condition:   Relapsed/Refractory Large Granular T Lymphocytic Leukemia Intervention:   Drug: Linperlisib Sponsors:   Institute of Hematology & Blood Diseases Hospital;   YL-Pharma Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 9, 2023 Category: Research Source Type: clinical trials

PI3K Delta Inhibitor in Relapsed / Refractory Autoimmune Hemolytic Anemia Patients After Receiving Two or More Lines of Therapy
Conditions:   Autoimmune Hemolytic Anemia;   Failure of Two Rounds of Treatment Intervention:   Drug: Linperlisib Sponsors:   Institute of Hematology & Blood Diseases Hospital;   YL-Pharma Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 9, 2023 Category: Research Source Type: clinical trials

British Axial Spondyloarthritis Inception Cohort
Condition:   Axial Spondyloarthritis Intervention:   Other: No intervenetion Sponsors:   The Leeds Teaching Hospitals NHS Trust;   Novartis;   Pfizer;   UCB Pharma Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 9, 2023 Category: Research Source Type: clinical trials

Efficacy and Safety of PI3K Inhibitors in Relapsed/Refractory Large Granular T Lymphocytic Leukemia
Condition:   Relapsed/Refractory Large Granular T Lymphocytic Leukemia Intervention:   Drug: Linperlisib Sponsors:   Institute of Hematology & Blood Diseases Hospital;   YL-Pharma Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 9, 2023 Category: Research Source Type: clinical trials

PI3K Delta Inhibitor in Relapsed / Refractory Autoimmune Hemolytic Anemia Patients After Receiving Two or More Lines of Therapy
Conditions:   Autoimmune Hemolytic Anemia;   Failure of Two Rounds of Treatment Intervention:   Drug: Linperlisib Sponsors:   Institute of Hematology & Blood Diseases Hospital;   YL-Pharma Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 9, 2023 Category: Research Source Type: clinical trials

British Axial Spondyloarthritis Inception Cohort
Condition:   Axial Spondyloarthritis Intervention:   Other: No intervenetion Sponsors:   The Leeds Teaching Hospitals NHS Trust;   Novartis;   Pfizer;   UCB Pharma Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 9, 2023 Category: Research Source Type: clinical trials